PT  - JOURNAL ARTICLE
AU  - Nso Nso Vialli
AU  - Daniel Antwi-Amoabeng
AU  - Bryce D. Beutler
AU  - Mark B. Ulanja
AU  - Jasmine Ghuman
AU  - Ahmed Hanfy
AU  - Joyce Nimo-Boampong
AU  - Sirri Atanga
AU  - Rajkumar Doshi
AU  - Sostanie Enoru
AU  - Nageshwara Gullapalli
TI  - Cardiac Adverse Events of Immune Checkpoint Inhibitors in Oncology Patients: A Systematic Review and Meta-Analysis
AID  - 10.1101/2020.06.01.20119719
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.01.20119719
4099  - http://medrxiv.org/content/early/2020/06/02/2020.06.01.20119719.short
4100  - http://medrxiv.org/content/early/2020/06/02/2020.06.01.20119719.full
AB  - Background Immune checkpoint inhibitors (ICIs) are novel therapeutic agents used for various types of cancer. ICIs have revolutionized cancer treatment and improved clinical outcomes among cancer patients. However, immune-related adverse effects of ICI therapy are common. Cardiovascular immune-related adverse events (irAEs) are rare but potentially life-threatening complications. We aimed to estimate the incidence of cardiovascular irAEs among patients undergoing ICI therapy for various malignancies.Methods We conducted this systematic review and meta-analysis by searching PubMed, Cochrane CENTRAL, Web of Science, and SCOPUS databases for relevant interventional trials reporting cardiovascular irAEs. We performed a single-arm meta-analysis using OpenMeta [Analyst] software of the following outcomes: myocarditis, pericardial effusion, heart failure, cardiomyopathy, atrial fibrillation, myocardial infarction, and cardiac arrest. We assessed the heterogeneity using the I2 test and managed to solve it with Cochrane’s leave-one-out method. The risk of bias was performed with the Cochrane’s risk of bias tool.Results A total of 26 studies were included. The incidence of irAEs follows: myocarditis: 0.5% (95% CI [0.1%-0.9%]); pericardial effusion: 0.5% (95% CI [0.1%-1.0%]); heart failure: 0.3% (95% CI [0.0%-0.5%]); cardiomyopathy: 0.3% (95% CI [-0.1%-0.6%]); atrial fibrillation: 7.6% (95% CI [1.0%-14.1%]); myocardial infarction: 0.4% (95% CI [0.0%-0.7%]); and cardiac arrest: 0.4% (95% CI [0.1%-0.8%]).Conclusion The most common cardiovascular irAEs were atrial fibrillation, myocarditis, and pericardial effusion. Although rare, data from post market surveillance will provide estimates of the long-term prevalence and prognosis in patients with ICI-associated cardiovascular complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This systematic review and meta-analysis is exempt from Institutional Review Board oversight.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the authors upon reasonable request.